Exploring the Potential Benefit of Epigenetic Modification: the LANTana Trial, an Open Label, Single Arm, Phase Ib Study to Evaluate the Effect of Pre-Treatment with ASTX727 (a Demethylating Agent) Followed by Lutathera (177Lu-Dotatate) in Patients with Progressive, Metastatic Neuroendocrine Tumours (Nets)
Endocrine abstracts（2022）
摘要
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要